Go-to-Market & Launch Strategy – UK

Establishing a company in the UK or launching a pharmaceutical brand is rarely straightforward. Regulatory, pricing, market access and competitive considerations all influence whether a UK launch is viable and attractive.

The Healthonauts support companies at this critical decision point. We help clients:

• Assess commercial and organisational feasibility

• Make robust go / no-go recommendations

• Define clear strategies and actions to achieve launch objectives – including resources, timelines and Interim and Fractional leadership

Once a launch decision is made, it can place exceptional demands on leadership capacity, specialist expertise and internal coordination The Healthonauts provide focused, hands-on support to help UK operating companies and EU HQs entering the UK, navigate, plan and execute a launch with confidence and speed.

We support you across the full go-to-market journey, combining deep knowledge of the UK regulatory environment, stakeholder landscape and launch execution requirements.

To accelerate time to market by placing experienced interim managers for all functions and, if required, manage the recruitment process. We take over the selection and management of suitable vendors for your product launch. We support you in creating a multi-channel launch plan and operational implementation of "day-to-day business", e.g. selecting and briefing marketing agencies or congresses planning.

Go-to-market services

• Interim General, Country or Business Unit Management

• Strategic consulting / strategic planning

• Go-to-market and first-launch strategy

• Launch Lead and launch excellence planning

• Multichannel launch planning and execution

• Internal and external stakeholder management

• Forecasting and financial control

Examples:

At Bio Products Laboratory, David supported critical decisions around brand and affiliate launches:
 

1. UK Launch Assessment

The decision to launch Gammaplex® 10% in the UK was complex, and David worked with all the internal cross-functional teams – notably regulatory, packaging, supply chain, finance, sales and marketing to model the challenges, opportunities and practicalities of progressing the launch. In addition, partnering with KOLs and NHS procurement ensured confidence in the market demand and market access journey that would provide brand uptake in the UK.

This enabled the company to determine that the launch would be profitable and attractive, not just to the UK P&L, but at a corporate level.
 

2. Post-Brexit EU affiliate strategy

In preparation for establishing an additional EU affiliate post Brexit, David completed a comprehensive commercial assessment of costs, opportunities and benefits. Following discussion with executive leadership, and based on strategic and financial modelling, he recommended continuing with a distribution partner rather than establishing a new operating company
 

3. Broader launch experience

David Lewis has supported the launch of many products in an operational, strategic or advisory capacity, across multiple disease areas, including genetic metabolic disorders (Pompe and Fabry), haemophilia, immunology, hepatitis, dermatology and schizophrenia.